Evidence map›Paper›PMID 42099041›Full record

ArticleTransplant infectious disease : an official journal of the Transplantation Society

Kidney Transplant Recipients Develop Nasal Mucosal Antibodies to SARS-CoV-2 With ACE2-Inhibiting Activity Following mRNA Vaccination.

Vera J C H Koomen, Christa E van der Gaast-deJongh, Fred van Opzeeland, Ria Philipsen, Marije C Baas, A Lianne Messchendorp, Frederike J Bemelman, Marcia M L Kho, Carla C Baan, Debbie van Baarle and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Transplant infectious disease : an official journal of the Transplantation Society. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Beyond the Blood: Insights Into Mucosal Immunity Among SARS-CoV-2-Vaccinated Kidney Transplant Recipients.Transplant infectious disease : an official journal of the Transplantation Society
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Vera J C H KoomenDepartment of Nephrology, Radboud University Medical Center Nijmegen, Nijmegen, the Netherlands.ORCID https://orcid.org/0000-0002-3572-2236
Christa E van der Gaast-deJonghDepartment of Laboratory Medicine, Laboratory of Medical Immunology, Radboud University Medical Center Nijmegen, Nijmegen, the Netherlands.
Fred van OpzeelandDepartment of Laboratory Medicine, Laboratory of Medical Immunology, Radboud University Medical Center Nijmegen, Nijmegen, the Netherlands.
Ria PhilipsenDepartment of Laboratory Medicine, Laboratory of Medical Immunology, Radboud University Medical Center Nijmegen, Nijmegen, the Netherlands.
Marije C BaasDepartment of Nephrology, Radboud University Medical Center Nijmegen, Nijmegen, the Netherlands.
A Lianne MesschendorpDivision of Nephrology, Department of Internal Medicine, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.ORCID https://orcid.org/0000-0002-2792-142X
Frederike J BemelmanRenal Transplant Unit, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.
Marcia M L KhoDepartment of Internal Medicine, Nephrology and Transplantation, Erasmus MC Transplant Institute, Erasmus Medical Center, Rotterdam, the Netherlands.
Carla C BaanDepartment of Internal Medicine, Nephrology and Transplantation, Erasmus MC Transplant Institute, Erasmus Medical Center, Rotterdam, the Netherlands.
Debbie van BaarleDepartment of Medical Microbiology and Infection Prevention, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
Jan-Stephan F SandersDivision of Nephrology, Department of Internal Medicine, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
Rob van BinnendijkCenter For Infectious Disease Control, National Institute for Public Health and the Environment, De Bilt, the Netherlands.
Gerco den HartogDepartment of Laboratory Medicine, Laboratory of Medical Immunology, Radboud University Medical Center Nijmegen, Nijmegen, the Netherlands.
Ron T GansevoortCenter For Infectious Disease Control, National Institute for Public Health and the Environment, De Bilt, the Netherlands.
Renate G van der MolenDepartment of Laboratory Medicine, Laboratory of Medical Immunology, Radboud University Medical Center Nijmegen, Nijmegen, the Netherlands.ORCID https://orcid.org/0000-0003-3113-6587
Luuk B HilbrandsDepartment of Nephrology, Radboud University Medical Center Nijmegen, Nijmegen, the Netherlands.ORCID https://orcid.org/0000-0002-4935-9765
Dimitri A DiavatopoulosDepartment of Laboratory Medicine, Laboratory of Medical Immunology, Radboud University Medical Center Nijmegen, Nijmegen, the Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLess than 60% of kidney transplant recipients (KTRs) become IgG seropositive for the viral spike (S) antigen following two COVID-19 vaccine doses, with a third dose increasing these numbers further. Mucosal antibodies play a critical role in protection against SARS-CoV-2 (re)infection; however, the presence and functionality of these antibodies after vaccination have not been well-studied in high-risk groups with reduced vaccine immunogenicity.

methodsWe assessed the concentration of ancestral S-specific antibodies in the nasal mucosa and in serum as well as their capacity to neutralize binding of the receptor-binding domain (RBD) to the ACE2 receptor in KTRs after two, three, and/or four vaccinations, compared with an age-matched control group after two vaccine doses.

resultsKTRs showed an increase in nasal and serum S-specific IgG and S-specific IgA geometric mean concentrations (GMCs) as well as ACE2 binding inhibition at 28 days after both two-dose and additional vaccinations compared to baseline, although postvaccination GMCs remained lower than in the control group. We observed a high correlation between nasal and serum antibody levels (r

conclusionsKTRs develop nasal mucosal antibodies, which are able to inhibit binding to ACE2 after COVID-19 vaccination, but at a lower concentration than controls. Mucosal sampling provides an accessible and minimally invasive addition to measuring serum antibodies for monitoring the response to vaccination at a population level.

Indexed as

Angiotensin-Converting Enzyme 2Antibodies, ViralCOVID-19COVID-19 VaccinesKidney TransplantationNasal MucosaSARS-CoV-2AdultAgedAntibodies, NeutralizingFemaleHumansImmunoglobulin AImmunoglobulin GMaleMiddle AgedACE2 protein, humanAngiotensin-Converting Enzyme 2Antibodies, NeutralizingAntibodies, ViralCOVID-19 VaccinesImmunoglobulin AImmunoglobulin GmRNA VaccinesSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2ACE2 inhibitionkidney transplant recipientsmucosal antibodiesneutralizing antibodiesSARS‐CoV‐2vaccination

Identifiers

PMID42099041
PMCPMC13450280

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.